Abstract 4924
Background
Abiraterone and enzalutamide represent the standard treatment in castration resistance prostate cancer (CRPC) patients, however, some patient displays primary resistance, and several studies investigated the role of the androgen receptor (AR) as a predictive biomarker of response to treatment (Conteduca, et al. Ann Oncol. 2017;28(7):1508-1516; Del Re, et al. BJU Int. 2019 doi: 10.1111/bju.14792). The present study is aimed at evaluating the role the AR in liquid biopsy to predict response to hormone treatment in CRPC patients.
Methods
Six ml of plasma samples were collected from patients affected by castration-resistant prostate cancer before the beginning of first-line hormonal treatment. Circulating free DNA and exosome-RNA were isolated for analysis of AR-gain and AR-V7 by digital droplet PCR.
Results
Eighty-four CRPC were prospectively enrolled in this study. 40 patients received abiraterone and 44 patients received enzalutamide as first-line hormonal therapy. AR-gain was detected in 12 patients (14.3%) and 36% were AR-V7+ at baseline. Median PFS and OS were significantly longer in AR-V7- vs AR-V7+ patients (24.3 vs 5.4 months, p < 0.0001; not reached vs 16.2 months, p < 0.0001, respectively). Patients carrying of the AR-gain had a median PFS of 4.8 vs 24.3 months of non-gained AR patients (P < 0.0001). Median OS was significantly longer in AR-no gain vs AR-gain (not reached vs 8.17 months, p < 0.0001). A significant correlation between AR-V7 and AR-gain was observed (r = 0.28; p = 0.01). In the univariate model, known risk factors for progression such as AR-V7, AR-gain, neutrophil/lymphocyte ratio and metastatic spread to either bone or lymph nodes were analysed. In multivariable analysis, only AR-V7 and AR gain were confirmed as independent predictive biomarkers (p < 0.0001 and p = 0.004, respectively).
Conclusions
The present study demonstrates that cfDNA and exosomal RNA are a reliable source of AR-variants and their detection predicts resistance to anti-hormonal therapy. The method is sensitive, fast and represents a convenient alternative to other potentially more expensive and less sensitive approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Conteduca: Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: Astellas; Travel/Accommodation/Expenses: Sanofi; Travel/Accommodation/Expenses: Bayer. U.F.F. De Giorgi: Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Sanofi; Advisory/Consultancy: Astellas; Advisory/Consultancy: Byer; Advisory/Consultancy: BMS; Honoraria (self): Ipsen; Advisory/Consultancy: Janssen; Advisory/Consultancy: Merk; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Sanofi; Travel/Accommodation/Expenses: BMS; Travel/Accommodation/Expenses: Ipsen; Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
1433 - Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets
Presenter: Sai-Hong Ou
Session: Poster Discussion 2 – Translational research
Resources:
Abstract
4105 - Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): data from TRIBE and FIRE-3 phase III trials.
Presenter: Alberto Puccini
Session: Poster Discussion 2 – Translational research
Resources:
Abstract
2381 - Oral Intestinal Alkaline Phosphatase Improves Efficacy of 5-FU in a Colorectal Cancer Mouse Model
Presenter: Christian Furlan Freguia
Session: Poster Discussion 2 – Translational research
Resources:
Abstract
1699 - Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases
Presenter: Filippo Pietrantonio
Session: Poster Discussion 2 – Translational research
Resources:
Abstract
3025 - Primary ovarian carcinomas arising in BRCA1 mutation carriers contain a small fraction of BRCA1-proficient cells, which rapidly repopulate tumor mass during neoadjuvant chemotherapy but become outgrown by BRCA1-deficient clones during platinum-free intervals
Presenter: Evgeny Imyanitov
Session: Poster Discussion 2 – Translational research
Resources:
Abstract
3707 - Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC)
Presenter: Francesca Battaglin
Session: Poster Discussion 2 – Translational research
Resources:
Abstract
Poster Discussion 2 – Translational research - Invited Discussant 92PD, 1880PD and 1881PD
Presenter: Alberto Bardelli
Session: Poster Discussion 2 – Translational research
Resources:
Slides
Webcast
Poster Discussion 2 – Translational research - Invited Discussant 93PD and 1882PD
Presenter: Dennis (Yuk-Ming) Lo
Session: Poster Discussion 2 – Translational research
Resources:
Slides
Webcast